Towards personalized treatment in atopic dermatitis-Reference-Cited by-同舟云学术

Towards personalized treatment in atopic dermatitis

Published:2019-02-26 Issue:5 Volume:19 Page:469-476
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

van der Schaft Jorien¹,Thijs Judith L.¹,Garritsen Floor M.¹,Balak D.¹,de Bruin-Weller Marjolein S.¹

Affiliation:

1. National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1583204

Reference54 articles.

1. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

3. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

4. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

5. Drug survival for azathioprine and enteric‐coated mycophenolate sodium in a long‐term daily practice cohort of adult patients with atopic dermatitis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Alleviation and Mechanism of Glabridin Liposome on Histamine-induced Atopic Dermatitis;Pharmacognosy Magazine;2024-03-11

2. Heat shock protein 90 (Hsp90) inhibitor STA-9090 (Ganetespib) ameliorates inflammation in a mouse model of atopic dermatitis;Cell Stress and Chaperones;2023-11

3. DOK3 promotes atopic dermatitis by enabling the phosphatase PP4C to inhibit the T cell signaling mediator CARD11;Science Signaling;2023-10-31

4. JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

5. Disease modification in inflammatory skin disorders: opportunities and challenges;Nature Reviews Drug Discovery;2023-07-13